Published in J Natl Cancer Inst on June 28, 2010
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol (2013) 2.73
Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. J Clin Oncol (2015) 2.70
Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group. J Clin Oncol (2014) 2.67
EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget (2015) 1.92
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol (2012) 1.44
Global incidence and outcome of testicular cancer. Clin Epidemiol (2013) 1.22
Beyond base pairs to bedside: a population perspective on how genomics can improve health. Am J Public Health (2011) 1.21
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol (2013) 1.13
Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst (2012) 1.04
Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol (2011) 0.99
Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer (2013) 0.95
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst (2014) 0.94
Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey. Support Care Cancer (2012) 0.93
Bleomycin-induced pulmonary fibrosis after tumor lysis syndrome in a case of advanced yolk sac tumor treated with bleomycin, etoposide and cisplatin (BEP) chemotherapy. Int J Clin Oncol (2011) 0.89
An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. Ecancermedicalscience (2016) 0.88
Testicular biopsy: clinical practice and interpretation. Asian J Androl (2011) 0.88
Assessing information and service needs of young adults with cancer at a single institution: the importance of information on cancer diagnosis, fertility preservation, diet, and exercise. Support Care Cancer (2013) 0.86
Patients with testicular cancer undergoing CT surveillance demonstrate a pitfall of radiation-induced cancer risk estimates: the timing paradox. Radiology (2012) 0.85
TRA-1-60(+), SSEA-4(+), POU5F1(+), SOX2(+), NANOG(+) Clones of Pluripotent Stem Cells in the Embryonal Carcinomas of the Testes. J Stem Cell Res Ther (2013) 0.83
Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy. Toxicol Sci (2014) 0.83
Palladium(II) and platinum(II) bind strongly to an engineered blue copper protein. Inorg Chem (2011) 0.82
Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin Oncol (2013) 0.82
Health-related quality of life, depression, and sexual function in testicular cancer survivors in a developing country: a Serbian experience. Support Care Cancer (2012) 0.81
Health-related quality of life in young men with testicular cancer: validation of the Cancer Assessment for Young Adults (CAYA). J Cancer Surviv (2013) 0.80
Evaluation of cloned cells, animal model, and ATRA sensitivity of human testicular yolk sac tumor. J Transl Med (2012) 0.78
A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology (2013) 0.78
Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecol Oncol Res Pract (2016) 0.78
Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet (2012) 0.78
Testicular cancer: a narrative review of the role of socioeconomic position from risk to survivorship. Urol Oncol (2011) 0.77
The clinical utility of testicular cancer risk loci. Genome Med (2011) 0.77
Management of stage I testicular germ cell tumours. Nat Rev Urol (2016) 0.75
Analysis of the prognosis of patients with testicular seminoma. Oncol Lett (2015) 0.75
Genetic changes associated with testicular cancer susceptibility. Semin Oncol (2016) 0.75
The management of low-stage non-seminomatous germ cell tumors. Oncol Rev (2012) 0.75
Advances in the treatment of testicular cancer. Transl Androl Urol (2015) 0.75
Vitamin D status among long-term survivors of testicular cancer. Oncotarget (2016) 0.75
Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology. BMC Cancer (2015) 0.75
The Danish Testicular Cancer database. Clin Epidemiol (2016) 0.75
The Sound of Silence: A Proxy for Platinum Toxicity. J Clin Oncol (2016) 0.75
Testicular germ cell tumor: Short and long-term side effects of treatment among survivors. Mol Clin Oncol (2016) 0.75
Impact of Non-Pulmonary Visceral Metastases in the Prognosis and Practice of Metastatic Testicular Germ Cell Tumors. Oncol Rev (2016) 0.75
Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results. Oncotarget (2016) 0.75
He had always wanted to ask an andrologist but had never done so. World J Clin Cases (2014) 0.75
A practical guide for evaluating gonadal germ cell tumor predisposition in differences of sex development. Am J Med Genet C Semin Med Genet (2017) 0.75
[Carcinoma in situ of the testis: predisposition, evolution and early detection]. Pathologe (2011) 0.75
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science (2003) 28.61
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Cardiovascular disease risk profiles. Am Heart J (1991) 21.65
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
Chronic health conditions in adult survivors of childhood cancer. N Engl J Med (2006) 19.97
Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med (2008) 9.83
Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol (2007) 8.05
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA (2008) 7.84
Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J (2003) 7.21
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA (2007) 5.74
Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA (2009) 5.09
Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart (2006) 4.94
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci (2008) 4.64
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation (2006) 4.35
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet (1991) 4.31
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Regulation of JNK signaling by GSTp. EMBO J (1999) 4.06
Cisplatin nephrotoxicity: a review. Am J Med Sci (2007) 4.05
Alzheimer's disease and Parkinson's disease. N Engl J Med (2003) 3.88
Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA (2009) 3.86
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet (2009) 3.83
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet (2005) 3.75
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin (2006) 3.67
Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst (2009) 3.52
TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest (2002) 3.48
Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol (2008) 3.44
Epidemiology of lung cancer. Chest (2003) 3.35
Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol (2005) 3.29
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol (1999) 2.98
Mobile phone-based remote patient monitoring system for management of hypertension in diabetic patients. Am J Hypertens (2007) 2.89
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2007) 2.68
Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. J Clin Oncol (2007) 2.65
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Reproduction rates after cancer treatment: experience from the Norwegian radium hospital. J Clin Oncol (2008) 2.61
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
Mortality after cure of testicular seminoma. J Clin Oncol (2004) 2.53
Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. J Clin Oncol (2007) 2.50
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol (2007) 2.36
CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol (2006) 2.34
Genetic analysis of radiation-induced changes in human gene expression. Nature (2009) 2.30
Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem (1998) 2.26
Molecular genetics of lung cancer. Annu Rev Med (2001) 2.25
Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol (1999) 2.25
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
Bleomycin-induced pneumonitis. Chest (2001) 2.13
Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol (2009) 2.11
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res (2004) 2.10
Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem (1994) 2.05
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol (2005) 1.93
Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol (1993) 1.91
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol (2000) 1.89
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol (2007) 1.88
Paternity following treatment for testicular cancer. J Natl Cancer Inst (2005) 1.87
Late relapse of testicular cancer. J Clin Oncol (1995) 1.87
Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol (2006) 1.85
TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol (2005) 1.78
Promoting a healthy lifestyle among cancer survivors. Hematol Oncol Clin North Am (2008) 1.75
Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a HuGE association review and meta-analysis. Am J Epidemiol (2008) 1.71
Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol (2003) 1.71
Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol (2003) 1.70
Metabolic and cardiovascular traits: an abundance of recently identified common genetic variants. Hum Mol Genet (2008) 1.65
Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis (2005) 1.65
ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res (2003) 1.64
Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation (2008) 1.64
TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.64
Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol (2008) 1.63
The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer (2003) 1.61
Patient accessible electronic health records: exploring recommendations for successful implementation strategies. J Med Internet Res (2008) 1.61
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Response shift theory: important implications for measuring quality of life in people with disability. Arch Phys Med Rehabil (2007) 1.57
The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. Eur Urol (2007) 1.57
Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res (1999) 1.57
Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science (1980) 1.56
Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2006) 1.55
Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst (2000) 1.54
Cisplatin and hypomagnesemia. Cancer Treat Rev (1999) 1.52
Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst (2005) 1.51
Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol (2003) 1.49
Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol (2007) 1.49
Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol (2001) 1.49
The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res (2002) 22.73
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA (2007) 5.74
Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA (2003) 5.27
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol (2004) 4.63
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med (2013) 4.49
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet (2009) 4.47
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 4.33
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
Physical activity and breast cancer: a systematic review. Epidemiology (2007) 3.90
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol (2003) 3.58
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst (2007) 3.55
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys (2004) 3.42
Patterns of care in the management of seminoma stage I: results from a European survey. BJU Int (2012) 3.41
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol (2005) 3.29
Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol (2008) 3.27
Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol (2003) 3.24
Anaplastic large-cell lymphoma in women with breast implants. JAMA (2008) 3.23
Incidence of retinoblastoma in children born after in-vitro fertilisation. Lancet (2003) 3.22
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol (2008) 3.15
Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst (2008) 3.13
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol (2007) 3.08
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol (2011) 3.05
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer (2004) 3.04
Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol (2005) 2.89
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys (2010) 2.84
Animal models for medical countermeasures to radiation exposure. Radiat Res (2010) 2.83
Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol (2002) 2.78
Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol (2005) 2.76
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol (2013) 2.73
Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol (2006) 2.71
Metformin: taking away the candy for cancer? Eur J Cancer (2010) 2.68
Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2007) 2.68
Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys (2010) 2.66
Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol (2002) 2.63
Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst (2009) 2.55
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol (2014) 2.45
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol (2007) 2.44
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ (2012) 2.44
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst (2002) 2.44
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol (2009) 2.42
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
The Hospital Anxiety and Depression Rating Scale: a cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry (2005) 2.37
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys (2010) 2.32
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol (2006) 2.32
Survivorship care plans in research and practice. CA Cancer J Clin (2012) 2.31
Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health (2007) 2.29
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol (2006) 2.28
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol (2009) 2.23
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood (2006) 2.18
Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood (2008) 2.17
Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med (2010) 2.17
American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol (2010) 2.14
American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol (2013) 2.14
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer (2011) 2.13
Chronic insomnia as a risk factor for developing anxiety and depression. Sleep (2007) 2.11
Hypospadias in sons of women exposed to diethylstilbestrol in utero: a cohort study. Lancet (2002) 2.10
Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol (2003) 2.09
Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol (2010) 2.06
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
General internists' preferences and knowledge about the care of adult survivors of childhood cancer: a cross-sectional survey. Ann Intern Med (2014) 2.03
Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys (2011) 2.03
Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol (2008) 2.03
Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst (2003) 2.02
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98
Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol (2003) 1.97
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96